10-Q: Imunon Reports Q3 2025 Results, Advances Ovarian Cancer Trial

Imunon, Inc. reported a reduced net loss for the nine months ended September 30, 2025, while advancing its lead ovarian cancer immunotherapy into Phase 3 and presenting positive Phase 2 data, despite ongoing going concern doubts.

Summary

• Net loss for the nine months ended September 30, 2025, decreased to $10.3 million from $14.6 million in the same period of 2024.
• Cash and cash equivalents stood at $5.3 million as of September 30, 2025, down from $5.9 million at December 31, 2024.
• Research and development expenses for the nine months ended September 30, 2025, were $5.3 million, a decrease from $9.4 million in the prior year, primarily due to reduced spending on OVATION 2, MRD, and PlaCCine vaccine trials.
• General and administrative expenses decreased to $5.1 million for the nine months ended September 30, 2025, from $5.6 million in 2024.
• The company initiated its pivotal Phase 3 OVATION 3 trial for IMNN-001 in advanced ovarian cancer, with the first patient enrolled in July 2025 and four sites currently recruiting.
• Positive Phase 2 OVATION 2 study data for IMNN-001 showed a median 13-month increase in overall survival and a 3-month increase in progression-free survival compared to standard of care alone.
• Phase 1 clinical trial results for the IMNN-101 COVID-19 booster vaccine demonstrated safety, tolerability, and durability of protection at six months with up to a 3-fold median increase in neutralizing antibody titers.
• A 15-for-1 reverse stock split was effected on July 25, 2025, to support future growth and maintain Nasdaq listing compliance.
• The number of authorized common shares was increased from 112,500,000 to 350,000,000 on July 11, 2025.
• A 15% stock dividend was approved on July 28, 2025, and issued on August 21, 2025.
• The company continues to operate with substantial doubt about its ability to continue as a going concern, with current capital not expected to fund operations for the next twelve months.

Sentiment

Score: 4

Explanation: While clinical progress for IMNN-001 is positive and IMNN-101 shows promise, the severe 'going concern' warning, declining cash balance, and reliance on dilutive financing for near-term operations significantly weigh down the sentiment. The company's long-term viability is heavily dependent on successful capital raises and clinical outcomes.

Positives

• Net loss for the nine months ended September 30, 2025, improved to $10.3 million from $14.6 million in the prior year.
• Cash used in operating activities for the nine months ended September 30, 2025, decreased to $10.2 million from $14.4 million in the prior year.
• IMNN-001's Phase 2 OVATION 2 study showed significant clinical benefits, including a median 13-month increase in overall survival and a 3-month increase in progression-free survival in advanced ovarian cancer patients.
• The Phase 2 OVATION 2 study also demonstrated a doubled chemotherapy response score (26.1% vs 13.0%) and improved surgical response rate (64.6% vs 52.1%) for IMNN-001 treated patients.
• IMNN-001 treatment showed a favorable safety profile with no serious immune-related adverse events.
• The FDA has aligned with the protocol for the pivotal Phase 3 OVATION 3 trial for IMNN-001, and patient enrollment has commenced.
• IMNN-101 COVID-19 booster vaccine Phase 1 trial demonstrated safety, tolerability, and durable immunogenicity with cross-reactivity against newer variants.
• The company successfully raised capital through ATM offerings and a private placement, securing $3,638,767 through September 30, 2025, and an additional $816,030 subsequent to that date.

Negatives

• The company has incurred substantial operating losses since inception, with a cumulative net loss of approximately $419 million as of September 30, 2025.
• Cash and cash equivalents decreased to $5.3 million as of September 30, 2025, from $5.9 million at December 31, 2024.
• The company's current capital is not expected to be sufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• Investment income decreased significantly to $117,000 for the nine months ended September 30, 2025, from $423,000 in the same period of 2024, primarily due to lower cash balances.
• The company has not generated significant revenue and does not expect to generate any from product sales in the next several years, if at all.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to significant operating losses and insufficient capital to fund operations for the next twelve months.
• The company's ability to raise additional capital may be adversely impacted by worsening global economic conditions and volatility in financial markets.
• There is inherent uncertainty in the drug development process, with a high risk of failure at every stage prior to regulatory approval.
• The company's ability to obtain or maintain U.S. Food and Drug Administration (FDA) and foreign regulatory approvals for its drug candidates is uncertain.
• Challenges exist in enrolling patients in clinical trials, which can impact timelines and costs.
• Risks relate to third parties' conduct of clinical trials, which are largely outside the company's direct control.
• Uncertainty surrounds government, private health insurers, and other third-party payers' coverage or reimbursement for potential drug candidates.
• The commercial potential of drug candidates in development is not assured.
• Changes in technologies for the treatment of cancer and the development of competitive drug candidates by others pose risks.
• Risks related to intellectual property, including prosecuting and enforcing patent claims, are present.
• Volatility in the market price of the company's common stock is a risk.
• Potential inability to maintain compliance with The Nasdaq Marketplace Rules, including the minimum bid price requirement, could lead to delisting.
• Any market activity involving short selling or other market making activities could result in a negative impact on the market price for the common stock.
• Future issuances or sales of common stock could result in significant dilution for existing stockholders.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future as it advances its drug candidates through development and clinical trials. Management plans to pursue additional capital funding through equity sales, debt facilities, partnerships, and out-licensing to address its substantial future capital requirements. The company intends to leverage its non-viral DNA technology to advance its TheraPlas modality for solid tumors and PlaCCine modality for infectious diseases, including seeking partnerships for IMNN-101. The Phase 3 OVATION 3 trial for IMNN-001 is actively enrolling patients, with plans to expand clinical sites and accelerate enrollment. The Phase I/II MRD study for IMNN-001 in combination with bevacizumab is expected to complete enrollment at 30 patients, with SLL data anticipated within one year of enrollment completion and final PFS data in approximately three years.

Management Comments

• Management has determined there is substantial doubt regarding our ability to continue as a going concern.
• Management's plan includes assessing current expenditures and reducing spending where necessary.
• Management will pursue additional capital funding in the public and private markets through equity sales and/or debt facilities.
• Management will pursue possible partnerships and collaborations.
• Management will pursue potential out-licensing for its drug candidates.
• We will continue to leverage these modalities and to advance the technological frontier of plasmid DNA based treatments to better serve patients with difficult-to-treat conditions.

Industry Context

Imunon operates in the highly competitive and rapidly evolving clinical-stage biotechnology sector, focusing on non-viral DNA technology for cancer immunotherapy and infectious disease vaccines. The positive Phase 2 results for IMNN-001 in advanced ovarian cancer, a malignancy with high mortality rates and significant unmet needs, position the company to potentially offer a novel approach, especially for patients not eligible for PARP inhibitors. The advancement to Phase 3 is a critical step in a field where new treatments are urgently sought. The IMNN-101 COVID-19 vaccine program, while showing promising Phase 1 data, faces a crowded and mature market dominated by established mRNA and viral vector vaccines, necessitating strategic partnerships to compete effectively. The company's focus on non-viral DNA delivery offers a potential differentiator in terms of safety, versatility, and stability compared to some conventional gene delivery methods.

Corporate Governance

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing and future equity financings due to the company's substantial capital requirements and going concern issues. The reverse stock split and stock dividend also impact share count and per-share metrics. Positive clinical trial results could increase share value, but financial instability remains a major concern.
• **Employees:** The company's financial instability and need to reduce spending could impact job security and compensation, although no specific changes were mentioned.
• **Patients (Ovarian Cancer):** Potential for a new, effective treatment option (IMNN-001) if Phase 3 trials are successful, offering hope for a difficult-to-treat condition.
• **Patients (Infectious Diseases):** Potential for a new vaccine technology (IMNN-101) with favorable safety and durability, though further development and partnerships are needed.
• **Creditors:** The 'going concern' warning indicates increased risk for creditors, as the company's ability to meet its obligations is uncertain without further capital.

Next Steps

• Expand clinical sites and accelerate patient enrollment for the Phase 3 OVATION 3 Study of IMNN-001.
• Complete enrollment of the Phase I/II MRD study for IMNN-001 in combination with bevacizumab once the ITT population reaches 30 patients.
• Anticipate SLL data from the MRD study within one year following the completion of enrollment and final PFS data approximately three years following enrollment completion.
• Submit results from the OVATION 2 Study for publication in a peer-reviewed medical journal.
• Present Phase 1 IMNN-101 clinical trial results at the 10th International Conference on Vaccines Research & Development in November 2025.
• Seek partnership and/or business development opportunities to develop the scientific and business case for IMNN-101 as a future vaccine.
• Pursue additional capital funding in the public and private markets through equity sales and/or debt facilities.
• Pursue possible partnerships and collaborations for drug candidates.
• Pursue potential out-licensing for drug candidates.
• Evaluate alternatives if unable to obtain sufficient capital to fund operations.

Key Dates

Recommendation

Imunon presents a high-risk, high-reward profile. The positive Phase 2 data for IMNN-001 in advanced ovarian cancer and its progression to Phase 3 are significant clinical milestones that could drive substantial value if successful. The IMNN-101 vaccine also shows promise. However, the company's severe 'going concern' warning, declining cash reserves, and continuous reliance on dilutive equity financing create substantial financial risk. An investor should 'hold' to monitor the progress of the Phase 3 trial and the company's ability to secure adequate non-dilutive or less dilutive funding, as the current financial situation makes a 'buy' too speculative despite clinical upside, and a 'sell' would forgo potential gains from successful clinical outcomes.

Keywords

Imunon, IMNN, biotechnology, clinical-stage, ovarian cancer, immunotherapy, IMNN-001, OVATION 3, Phase 3 trial, PlaCCine, COVID-19 vaccine, IMNN-101, DNA-based therapy, TheraPlas, oncology, vaccine development, SEC filing, 10-Q, financial results, going concern, capital raise, Nasdaq listing